



Cite this: *RSC Adv.*, 2023, 13, 13715

Efficient Buchwald–Hartwig and nitrene-mediated five-membered ring closure approaches to the total synthesis of quindoline. Unexpected direct conversion of a nitro group into a phosphazene†

Elida N. Thobokholt,^{ID} Sebastián O. Simonetti,^{ID} Teodoro S. Kaufman,^{ID} Enrique L. Larghi^{ID}* and Andrea B. J. Bracca^{ID}*

Two total syntheses of quindoline, which take place through the intermediacy of 3-nitroquinoline derivatives, are reported. The general synthetic sequence involves construction of the latter by mechanochemical condensation of benzaldehydes with 2-amino-nitrostyrene, followed either by reduction of the nitro group of the heterocycle and Buchwald–Hartwig cyclization or by a nitrene-mediated cyclization under solventless conditions. Use of PPh_3 to generate the nitrene resulted in the unprecedented formation of a phosphazene in place of quindoline. This unexpected transformation was explained by means of DFT computations.

Received 13th April 2023
Accepted 25th April 2023

DOI: 10.1039/d3ra02468g

rsc.li/rsc-advances

Introduction

The indoloquinolines are a small family of heterocyclic natural products, which display fused indole and quinoline rings. They have been isolated from various plants around the world belonging to three different genera. These include the African thin-stemmed twining and scrambling shrub *Cryptolepis sanguinolenta* (Periplocaceae), the Chinese *Isatis indigotica* and *I. tinctoria* (Brassicaceae), the indian *Justicia betonica* L. (Acanthaceae),¹ the American evergreen climbing shrub *J. secunda* Vahl and the Brazilian *Sida acuta*,² *S. rhombifolia* and *S. cordifolia*³ (Malvaceae).

The natural indoloquinolines share two main characteristics: their vegetal sources enjoy wide use in different traditional medicine systems, being employed to treat a variety of illnesses and conditions;⁴ in addition, the natural products are scarcely decorated by alkyl or oxygen bearing functionalities.⁵

Most of the natural indoloquinolines are monomeric (Fig. 1) and display their heterocyclic components fused to yield different skeletal arrangements. These comprise, among others, quindoline (1),⁶ methylquindoline-11-carboxylate (1a),⁷ cryptolepine (2),⁸ 11-hydroxycryptolepine (3),⁹ 11-isopropyl cryptolepine (4),^{10a} neocryptolepine (5),¹¹ quindolinone (6),^{10b} isocryptolepine (7)^{9b,10c} and quinindoline (8).¹

Enlarging the family, a handful of dimeric indoloquinolines have also been reported as minor alkaloids from *Cryptolepis sanguinolenta*. Among them are cryptoquindoline (9)⁹ and





Fig. 1 Chemical structures of selected indoloquinoline alkaloids. Quindoline (1), methylquindoline-11-carboxylate (1a), cryptolepine (2), 11-hydroxycryptolepine (3), 11-isopropyl cryptolepine (4), neocryptolepine (5), quindolinone (6), isocryptolepine (7) quinindoline (8), 6-methylquinindoline (8a), cryptoquindoline (9) and biscryptolepine (10).

Instituto de Química Rosario (IQUIR, CONICET-UNR), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 2000, Rosario, Argentina. E-mail: bracca@iquir-conicet.gov.ar; larghi@iquir-conicet.gov.ar

† Electronic supplementary information (ESI) available: NMR spectra of the compounds and details of DFT calculations. See DOI: <https://doi.org/10.1039/d3ra02468g>





Scheme 1 Synthetic approaches to quindoline. Previous strategy and a proposed new retrosynthetic analysis of quindoline (1).

biscryptolepine (10),^{9b} as well as quindolinocryptotackieine^{12a} cryptolepicarboline,^{12b} cryptospirolepine,^{12c} and cryptomisine.^{12d}

We have recently focused on the synthesis of indoloquinolines,¹³ contributing with the total syntheses of quindoline (1)¹⁴ and neocryptolepine (5).¹⁵ Access to the unnatural 6-methyl-quinindoline (8a) was also disclosed.¹⁵

The synthesis of indoloquinolines remains an active field. Quindoline (1) has been isolated from different plants worldwide;^{3,5a,6,16,17} this simple and bioactive monomeric indoloquinoline is a synthetic precursor of the most widely known cryptolepine (2).¹⁸

During our previous synthesis of quindoline, we observed that attempts to perform a nitrene-based cyclization of the five-membered ring by PPh₃-mediated reduction of the nitrobenzene derivative 11 resulted exclusively in the formation of the indazolo[2,3-a]quinoline 13,¹⁴ whereas an alternative Buchwald-Hartwig approach from the bromo-aniline 12 gave the product (1) in good yield (Scheme 1). In an attempt to avoid these diverging paths, we considered exchanging the places of the nitrogen functionality and the cyclization facilitating group, when required, as a viable alternative.

Retrosynthetically, this concept is shown in 14a, where the nitrogen functionality is supported by the quinoline moiety. In turn, appropriate C–C and C–N disconnections of the heterocyclic ring in the latter unveil the aminobenzaldehyde 15 and the nitrostyrene derivative 16 as its starting materials, conjecturing that a Friedländer condensation would serve as a constructive solution.

Therefore, herein we wish to report a new strategic approach toward the total synthesis of quindoline, employing a ring building route of the type A + D → ABD → ABCD, in compliance with the retrosynthetic analysis of Scheme 1.

Results and discussion


According to the retrosynthetic analysis, the synthetic sequence commenced with the preparation of the proposed 2,3-disubstituted quinoline intermediate exemplified by 14. To that end, 2-bromobenzaldehyde (17) was reacted with nitromethane and subjected to a Henry nitroaldol condensation under NH₄AcO promotion, in refluxing AcOH, to afford 18 in 62% isolated yield,¹⁹ whereas the slightly unstable 2-aminobenzaldehyde (15) was conveniently obtained in almost quantitative yield, by an iron-mediated reduction of 2-nitrobenzaldehyde (14) in an EtOH–0.1 N HCl medium (Scheme 2).¹⁴

Next, the projected Friedländer-type condensation was undertaken, employing a solvent-free strategy where 15 and 18 were thoroughly mixed with neutral alumina. Under these conditions, a hardly separable mixture of 1,2-dihydroquinoline 19 and the corresponding quinoline 20 were obtained in 98% combined yield.²⁰

Considering that formation of the quinoline could not be driven to completion, it was assumed that its presence among the products could be the result of an air-mediated oxidation of the reaction mixture. Further, in view of the difficulties posed by the separation of both products, the dehydrogenation stage was optimized on the mixture, as shown in Table 1.

Unexpectedly, the microwaves-assisted reaction with activated MnO₂ in CH₂Cl₂ gave a complex mixture of unidentified products (entry 1), whereas exposure to iodine in EtOH for 3 h at room temperature (entry 2) and to KMnO₄ in acetone (entry 3) gave unsatisfactory yields (4 and 6%, respectively).


A slightly better performance was observed with FeCl₃ in a CH₂Cl₂ : H₂O (10 : 1, v/v) solvent mixture (29% yield) under catalytic amounts of DDQ after 22 h at room temperature (entry 4). However, still unsatisfactory results were obtained with *p*-benzoquinone (entry 5) in refluxing dioxane (72 h, 35% yield) and with the K₂CrO₄/KHSO₄ reagent supported on SiO₂ (entry 6)



Scheme 2 Reagents and conditions: (a) MeNO₂, NH₄AcO, AcOH, 118 °C, 24 h (62%); (b) Fe⁰, 0.1 N HCl, EtOH, 90 °C, 4 h (99%); (c) neutral Al₂O₃, 50 °C, 24 h (98%); (d) DDQ, CH₂Cl₂, RT, 30 min (98%); (e) Fe⁰, 0.1 N HCl, EtOH, 90 °C, 4 h (99%); (f) Pd(MeCN)₂Cl₂, DPPF, ^tBuOK, THF, 100 °C, 72 h (78%).



Table 1 Optimization of the dehydrogenation of 1,2-dihydroquinoline 19



Entry no.	Reagents	Solvent	Temp. (°C)	Time (h)	Yield (%)
1	MnO ₂	CH ₂ Cl ₂	100	0.5	0 ^a
2	I ₂	EtOH	RT	3	4
3	KMnO ₄	Me ₂ CO	RT	10	6
4	FeCl ₃ , DDQ (cat.)	CH ₂ Cl ₂ : H ₂ O (10 : 1, v/v)	RT	22	29
5	<i>p</i> -Benzoquinone	Dioxane	Reflux	72	35
6	KHSO ₄ , K ₂ CrO ₄ , SiO ₂	CH ₂ Cl ₂	RT	20	38
7	Mn(OAc) ₃ ·2H ₂ O DDQ (cat.)	CH ₂ Cl ₂	RT	12	51
8	CuI	DMSO	120	1	78
9	DDQ	CH ₂ Cl ₂	RT	0.5	98

^a Performed under microwave irradiation (maximum power: 150 W); complex mixture of unidentifiable compounds.

under solventless conditions, when it was left to react for 20 h at room temperature (38% yield).

In view of these meagre results, an additional series of conditions was tested. The use of Mn(OAc)₃·2H₂O as oxidant, with the addition of catalytic amounts of DDQ, for 12 h at room temperature gave **20** in a moderate 51% yield (entry 7). However, an improved 78% yield was achieved after a 1 h reaction with CuI in DMSO at 120 °C (entry 8). Finally, it was found that exposure of **19** to DDQ at room temperature was capable of affording the required quinoline **20** in 98% yield after 30 min (entry 9).

With an efficient protocol to access the 3-nitroquinoline in hand, the next step in the sequence involved its modification toward a cyclizable substrate.

Therefore, **20** was reduced to the 3-aminoquinoline **21** in 99% yield with iron turnings in EtOH to which 0.1 N HCl was added.¹⁴

Then, aiming to optimize the yields, the final cyclization stage was performed under different conditions, as shown in Table 2.

The first attempt, an intramolecular amination of the bromide under ^tBuOK promotion in DMSO at 130 °C for 24 h afforded the expected product in 43% yield (entry 1),^{21a} whereas


an analogous photostimulated cyclization at room temperature using violet LED light proceeded in 57% yield (entry 2). On the other hand, the reaction with CuI and K₂CO₃ in DMF at 110 °C, under modified Ullman conditions and proline as ligand, gave **1** in 56% yield after 24 h (entry 3).

Gratefully, the moderate performance of these reactions was surpassed by the Buchwald–Hartwig cyclization of **21** in THF under Pd(MeCN)₂Cl₂ catalysis, which proceeded uneventfully to afford **1** in 78% yield, when DPPF was employed as ligand and ^tBuOK as base (entry 4). The spectroscopic data of the tetracycle were in full agreement with those of the literature.¹⁴

After demonstrating that the new strategy was capable to successfully afford quinoline through a Buchwald–Hartwig reaction, our attention was turned toward the use of a nitrene as cyclization intermediate. To that end, benzaldehyde (**22**) was submitted to a Henry reaction under microwaves irradiation, affording nitrostyrene (**23**) in 70% yield after 1.5 h (Scheme 3).

Next, the reaction of **23** and freshly prepared **15** under promotion by basic alumina, gave a mixture of the heterocycles **24** and **25** in 99% combined yield, after 24 h at 50 °C. Conversion of the mixture to 3-nitroquinoline **25** took place in 82% yield by stirring for 30 min at room temperature, with DDQ as oxidant.

Table 2 Conditions for the intramolecular cyclization of 21



Entry no.	Reagents	Solvent	Temp. (°C)	Time (h)	Yield (%)
1	^t BuOK	DMSO	130	24	43
2	^t BuOK, (violet LED)	DMSO	RT	48	57
3	CuI, proline, K ₂ CO ₃	DMF	110	24	56
4	Pd(MeCN) ₂ Cl ₂ , DPPF, ^t BuOK	THF	100	72	78



nitrene intermediate by two paths: (1) a stepwise path that involves the break of the N–P bond in **iii** and the formation of a “N–O–P” species as **iv**. Subsequently, **iv** could release Me₃PO with the concomitant formation of the nitrene intermediate. (2) Another alternative is the formation of the nitrene intermediate **v** through the concerted elimination of Me₃PO as previously was described for bisphosphines.²⁷

Whereas it was not possible to find out the transition state of the concerted mechanism (even a dissociate transition state), the intermediate **iv** was observed in an optimization of **iii**. Therefore, this intermediate was re-optimized and furnished an energy which resulted $-0.12 \text{ kcal mol}^{-1}$ lower than **iii**. The transition state (**TSiv**) for the formation of the nitrene intermediate (**v**) afforded an activation energy of $7.23 \text{ kcal mol}^{-1}$ with an exergonic energy of $-24.05 \text{ kcal mol}^{-1}$ in favour of **v**.

This nitrene intermediate could continue the reaction along two paths (Scheme 5).²⁹ One of them is the formation of the cyclized product through the insertion of the nitrene species at C–H bond of the aromatic ring (Path b). The other possibility (observed experimentally) is the formation of the phosphazene through the coupling between the nitrene and the phosphine (Path a). The calculations of these paths show that the formation of the phosphazene product presents an activation energy of $24.65 \text{ kcal mol}^{-1}$ (**TSva**), whereas the formation of the cyclized product (**TSvb**) is 3 kcal mol^{-1} higher than the phosphazene product. While the formation of the cyclized product

presents a lower energy balance regards to the nitrene than the phosphazene product ($-69.61 \text{ kcal mol}^{-1}$ vs. $-52.41 \text{ kcal mol}^{-1}$, respectively) the energy gap in the activation energy is enough to explain the results obtained experimentally.

Therefore, based on our theoretical calculations, it can be assumed that the phosphazene product could be accessed from nitrene **v**, which, in turn, is obtained through the gradual cleavage of the oxazaphosphane **iii** intermediate (Scheme 4). Exchange of oxygen atoms in the case of bisphosphines (such as DPPF) probably also provides the intermediate nitrene, but cyclization might be favored instead of a phosphazene product due to steric hindrance. However, a deeper mechanistic investigation may be required to confirm this hypothesis and rule out an electronic factor.

Conclusions

In conclusion, we have developed simple and efficient total syntheses of quindoline, a naturally-occurring bioactive indoloquinoline, based on Buchwald–Hartwig and nitrene-mediated five-membered ring closure approaches, employing 3-nitroquinoline derivatives as key intermediates. The Buchwald–Hartwig alternative afforded quindoline in 5 linear steps and 46% overall yield from 2-bromobenzaldehyde (73% from 2-nitrobenzaldehyde), whereas the nitrene-based synthesis afforded the natural product in only 4 steps and 47% overall yield (66% from 2-nitrobenzaldehyde).


Interestingly, phosphazene **27** was obtained in an unprecedented way by reaction with 3-nitroquinoline **25** and PPh₃. DFT calculations were carried out to shed light on its formation and confirmed a nitrene as key intermediate in the mechanistic pathway. Further investigation on the scope and limitations of the formation of phosphazenes with other nitroarenes is underway and the results will be reported in due time.

Both strategies, which were devoid of protecting groups, use 2-nitrobenzaldehyde as starting material. Simplicity of these routes suggests that they can inspire the synthesis of more complex heterocycles as analogs of the natural product.

Experimental

General information

The reactions were executed with oven-dried glassware under dry nitrogen or argon atmospheres. Anhydrous DMF was obtained by heating the PA grade product over BaO for 4 h, followed by distillation under reduced pressure. Anhydrous CH₂Cl₂ was obtained by refluxing 4 h the analytical grade product over CaH₂, followed by distillation. Anhydrous toluene was obtained by reflux of the solvent over sodium, to which benzophenone was added, followed by distillation from the deep-blue sodium benzophenone ketyl. Anhydrous EtOH was obtained by refluxing the analytical grade solvent for 4 h over magnesium ethoxide, prepared *in situ* from magnesium turnings activated with iodine, and distilling the solvent from the thus formed magnesium ethoxide. Anhydrous solvents were stored in dry Young ampoules. All other reagents were used as received.



Scheme 5 Above: Routes for the obtention of phosphazene **vi** or quindoline (**1**) from nitrene **v**. Below: Calculations for the obtention of the observed phosphazene product. calculated at M062x/6-31g**/6-311+g**. Energies are in kcal mol⁻¹, distances in Å and Wiberg index in parentheses.



The flash column chromatographies were carried out employing Merck's silica gel 60H. The elutions were performed under positive pressure with mixtures of hexane and EtOAc, and employing gradient of solvent polarity techniques. The new compounds exhibited single spots on TLC plates (silica gel 60 GF₂₅₄) developed in different hexane/EtOAc solvent systems. The spots were detected by exposure of the plates to 254 nm UV light, followed by spraying with ethanolic *p*-anisaldehyde/sulfuric acid reagent or with the Dragendorff reagent (Munier and Macheboeuf modification).³⁰ The plates were carefully heated, for improving selectivity.

Apparatus

The melting points were determined on a model 350 Ernst Leitz Wetzlar hot-stage microscope and are reported uncorrected. The IR spectra were acquired in a Prestige 21 spectrophotometer (Shimadzu Corp., Tokyo, Japan), as thin films between NaCl plates or as solid dispersions in KBr disks.

The NMR spectra were acquired in CDCl₃ at 300.13 (¹H), 75.48 (¹³C) or 188.31 (¹⁹P) MHz on a Bruker Avance spectrometer. The peak of residual CHCl₃ ($\delta_{\text{H}} = 7.26$ ppm), and the signal of CDCl₃ ($\delta_{\text{C}} = 77.0$ ppm) were used as internal standards, respectively. The chemical shifts are informed in parts per million (δ scale) and the *J*-values are given in Hertz. When required, selective TOCSY and 2D-NMR experiments (COSY, HMBC and HMQC) were also obtained. The high-resolution mass spectra were obtained from UMYMFOR (Buenos Aires, Argentina) with a Bruker MicroTOF-Q II instrument. Detection of the ions was performed in electrospray ionization, positive ion mode.

(*E*)-1-Bromo-2-(2-nitrovinyl)benzene (18)

A solution of 2-bromobenzaldehyde (17, 113 mg, 0.61 mmol) in glacial acetic acid (1.5 mL) was treated portion-wise with NH₄AcO (94 mg, 1.22 mmol) and the mixture was stirred for 15 minutes at room temperature. Then, MeNO₂ (149.3 mg, 2.44 mmol) was slowly transferred to the reaction medium and the system was heated under reflux for 24 h. Brine was added (30 mL) and the product was extracted with EtOAc (3 × 30 mL). The combined organic phases were dried (MgSO₄), filtered and concentrated under reduced pressure. The crude material was purified by chromatography to give **18** (86 mg, 62%), as a yellow solid. Mp 88–90 °C (Lit.: 87–88 °C);^{19a} IR (KBr, ν): 3395, 3750, 3422, 1636, 1458, 1340, 1111, 945 and 758 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.40 (1H, d, *J* = 13.7, H-2'), 7.69 (1H, dd, *J* = 7.4 and 1.9, H-3), 7.58 (1H, dd, *J* = 7.4 and 2.1, H-6), 7.54 (1H, d, *J* = 13.7, H-1'), 7.38 (1H, td, *J* = 7.4 and 1.9, H-5) and 7.33 (1H, td, *J* = 7.4 and 2.1, H-1'); ¹³C NMR (75 MHz, CDCl₃): δ = 139.0 (C-1'), 137.5 (C-2'), 134.0 (C-3), 133.0 (C-4), 130.0 (C-2), 128.5 (C-6), 128.1 (C-5) and 126.3 (C-1).

2-Aminobenzaldehyde (15)

A stirred solution of 2-nitrobenzaldehyde (**14**, 206 mg, 1.36 mmol) in EtOH (8 mL) to which a 0.1 N HCl solution (680 μ L, 68 μ mol) was added, was treated with Fe⁰ turnings (299 mg, 5.34 mmol) and the reaction was heated under reflux for 4 h. After

cooling to room temperature, the reaction mixture was diluted with EtOAc (30 mL), filtered through Celite®, and the filtrate was neutralized with saturated NaHCO₃ solution and washed with brine (10 mL). The product was extracted with EtOAc (3 × 30 mL), and the combined organic phases were dried (MgSO₄), filtered and concentrated under reduced pressure. After filtration through a shorth pad of Celite, the desired product **15** was obtained (160 mg, 99%), as a yellow solid.¹⁸ Mp 32–34 °C; IR (KBr, ν): 3458, 3352, 3063, 2746, 1651, 1556, 1396, 1157, 1028 and 752 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 9.87 (1H, s, CHO), 7.48 (1H, dd, *J* = 7.8 and 1.5, H-6), 7.34–7.28 (1H, m, H-4), 6.75 (1H, dt, *J* = 7.4 and 0.7, H-5), 6.64 (1H, d, *J* = 8.3, H-3) and 6.11 (2H, bs, NH₂); ¹³C NMR (75 MHz, CDCl₃): δ = 194.1 (CHO), 149.9 (C-2), 135.7 (C-4), 135.2 (C-6), 118.9 (C-5), 116.4 (C-1) and 116.0 (C-3).

2-(2-Bromophenyl)-3-nitroquinoline (20)

2-Bromonitrostyrene (21.6 mg, 0.095 mmol) was added to a mixture containing neutral Al₂O₃ (95 mg, 1.07 mmol) and 2-aminobenzaldehyde (11.5 mg, 0.095 mmol) and the reaction was heated at 50 °C for 24 h. After cooling to room temperature, the crude material was chromatographed to give a barely separable mixture of 2-(2-bromophenyl)-3-nitro-1,2-dihydroquinoline (**19**) and quinoline **20** (30.9 mg, 98%), as a reddish solid.²⁰

2-(2-Bromophenyl)-3-nitro-1,2-dihydroquinoline (19)

Mp 104–106 °C; IR (KBr, ν): 3995, 3977, 3400, 3381, 1634, 1606, 748, 603 and 588 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.19 (1H, s, H-4), 7.61 (1H, dd, *J* = 7.7 and 1.0, H-5), 7.24–7.21 (3H, m, H-7, H-4' and H-5'), 7.18–7.12 (2H, m, H-3' and H-6'), 6.70 (1H, td, *J* = 7.5 and 0.8, H-6), 6.45 (1H, d, *J* = 6.4, H-8), 6.43 (s, 1H, H-1') and 5.09 (s, 1H, H-1); ¹³C NMR (75 MHz, CDCl₃): δ = 143.8 (C-8a), 139.2 (C-4a), 139.1 (C-3), 134.2 (C-6'), 133.5 (C-5), 133.0 (C-4), 131.3 (C-5'), 130.1 (C-3'), 128.3 (C-7), 127.9 (C-4'), 121.4 (C-2'), 118.9 (C-6), 115.2 (C-1'), 114.0 (C-8) and 53.8 (C-2).

Without further purification, a stirred solution of dihydroquinoline **19** (15.7 mg, 0.05 mmol) in anhydrous CH₂Cl₂ (1 mL) was treated with DDQ (12.8 mg, 0.05 mmol) and the reaction was stirred at room temperature for 30 minutes. Next, saturated NaHCO₃ solution (7 mL) was added and the products were extracted with EtOAc (3 × 30 mL). The combined organic phases were dried (MgSO₄), filtered and concentrated under reduced pressure. The residue was purified by chromatography to give the desired nitroquinoline **20** (15.3 mg, 98%), as a yellow solid. Mp 95–97 °C (Lit.: 95–97 °C);³¹ IR (KBr, ν): 1603, 1553, 1520, 1348, 1335, 831, 789 and 760 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.99 (1H, s, H-4), 8.26 (1H, d, *J* = 8.7, H-5), 8.07 (1H, d, *J* = 8.2, H-8), 7.96 (1H, dt, *J* = 7.7 and 1.4, H-7), 7.76 (1H, dt, *J* = 7.6 and 1.0, H-6), 7.66 (1H, d, *J* = 7.8, H-3'), 7.51 (ddd, 2H, *J* = 9.9, 7.6 and 2.3) and 7.36 (ddd, 1H, *J* = 8.8, 6.7 and 2.3, H-4'); ¹³C NMR (75 MHz, CDCl₃): δ = 152.0 (C-2), 148.3 (C-8a), 142.8 (C-1'), 139.2 (C-3), 133.2 (C-4), 133.1 (C-7), 132.3 (C-3'), 130.1 (C-4'), 129.9 (C-5'), 129.6 (C-5), 128.8 (C-8), 128.7 (C-6), 127.5 (C-6'), 125.8 (C-4a) and 121.6 (C-2').



2-(2'-Bromophenyl)-3-aminoquinoline (21)^{21,31}

Fe⁰ turnings (67.7 mg, 1.20 mmol) were added to a stirred solution of the nitroquinoline **18** (66.4 mg, 0.2 mmol) in EtOH (2.7 mL). The mixture was then treated with a 0.1 N solution of HCl (100 μ L, 100 μ mol) and heated under reflux for 4 h. Then, the reaction system was diluted with EtOAc and filtered through Celite®. After diluting with EtOAc (30 mL) and washing with saturated NaHCO₃ (10 mL), the product was extracted with EtOAc (3 \times 30 mL); the combined organic layers were dried (MgSO₄), filtered and concentrated under reduced pressure, affording **21** (60 mg, 99%), as a light yellow oil. IR (film, ν): 3997, 3462, 3129, 2851, 1556, 1417, 1250, 1188, 881 and 665 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.90 (1H, t, J = 4.7, H-8), 7.60 (1H, d, J = 7.9, H-5), 7.55–7.52 (1H, m, H-6), 7.38–7.33 (4H, m, H-7, H-3', H-5' and H-6'), 7.25–7.19 (1H, m, H-4), 7.14 (1H, s, H-4) and 3.65 (2H, bs, NH₂); ¹³C NMR (75 MHz, CDCl₃): δ = 149.4 (C-2), 141.3 (C-3), 138.0 (C-1'), 137.1 (C-8a), 132.2 (C-3'), 130.0 (C-6'), 129.4 (C-4'), 128.4 (C-4a), 128.2 (C-8), 127.2 (C-5'), 126.0 (C-6), 124.9 (C-5), 124.5 (C-7), 121.6 (C-2') and 115.2 (C-4).

10H-Indolo[3,2-*b*]quinoline (quindoline, 1)

A mixture of Pd(MeCN)₂Cl₂ (1.6 mg, 0.006 mmol) in THF (1.2 mL) was treated with DPPF (16.0 mg, 0.03 mmol) and stirred at room temperature under inert atmosphere for 12 h. Then, the aminoquinoline **21** (18.4 mg, 0.06 mmol) was added and the reaction was stirred at room temperature for 1 h. After the addition of ^tBuOK (19.3 mg, 0.14 mmol), the mixture was stirred under reflux for 72 h. The reaction mixture was diluted with EtOAc and filtered through Celite®. After evaporation of the solvent under reduced pressure, the residue was purified by chromatography to give the desired quindoline (**1**, 10.2 mg, 78%), as a yellow solid.³² Mp 201–203 °C; IR (KBr, ν): 3163, 3086, 2922, 2851, 1608, 1481, 1338, 1223, 737 and 716 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.54 (1H, d, J = 7.9, H-6), 8.33 (1H, d, J = 8.6, H-4), 8.27 (1H, b, H-10), 8.02 (1H, s, H-11), 7.92 (1H, dd, J = 8.3 and 1.2, H-1), 7.65 (1H, ddd, J = 7.6, 6.9 and 1.5, H-3), 7.55 (2H, ddd, J = 8.5, 8.4 and 1.2, H-8 and H-2), 7.45 (1H, d, J = 8.2, H-9) and 7.33 (1H, td, J = 7.5 and 0.8, H-7); ¹³C NMR (75 MHz, CDCl₃): δ = 146.5 (C-5a), 144.4 (C-4a), 143.6 (C-9a), 132.4 (C-10a), 129.9 (C-8), 129.1 (C-4), 127.2 (C-1), 127.0 (C-11a), 126.6 (C-3), 125.3 (C-2), 122.2 (C-6), 122.1 (C-5b), 120.4 (C-7), 113.2 (C-11) and 111.0 (C-9).

(*E*)-(2-Nitrovinyl)benzene (23)

A mixture of benzaldehyde (**22**, 106.1 mg, 1 mmol), MeNO₂ (2 mL) and NH₄Ac (39.7 mg, 0.51 mmol) was transferred to a microwave tube and irradiated in a microwave oven at 90 °C for 60 min. Once the reaction was finished, the volatiles were removed under reduced pressure and the crude material was purified by chromatography to give the nitrostyrene **23** (105 mg, 70.4%), as a yellow solid. Mp 58–60 °C (Lit.: 57–58 °C);^{19b} IR (KBr, ν): 1634, 1514, 1495, 1449, 1346 and 594 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 8.0 (1H, d, J = 14.1, H-2'), 7.59 (2H, d, J = 13.7, H-2 and H-6), 7.54 (1H, d, J = 1.9, H-1') and 7.51–7.42 (3H, m, H-3, H-4 and H-5); ¹³C NMR (75 MHz, CDCl₃): δ = 139.1 (C-

2'), 137.1 (C-2 and C-6), 132.1 (C-3 and C-5), 130.1 (C-1), 129.4 (C-1') and 129.1 (C-4).

2-Phenyl-3-nitroquinoline (25)

A mixture of basic Al₂O₃ (172 mg, 1.67 mmol), 2-amino benzaldehyde (**15**, 20.9 mg, 0.17 mmol) and nitrostyrene (**23**, 36.1 mg, 0.24 mmol) was heated at 50 °C for 24 h. Then, the system was cooled at room temperature and the crude material was purified by chromatography to give a mixture of 2-phenyl-3-nitrodihydro-quinoline (**24**) and 2-phenyl-3-nitroquinoline (**25**) as a red solid (43 mg, 99%).

Compound **24**: HRMS (ESI⁺) calcd. for C₁₅H₁₂N₂NaO₂ ([M + Na]⁺) m/z = 275.0791; found: m/z = 275.0794.

Without further treatment, the mixture of dihydroquinoline **24** and nitroquinoline **25** (28.2 mg, 0.11 mmol) was dissolved in anhydrous CH₂Cl₂ (1 mL) and treated with DDQ (28.1 mg, 0.12 mmol). The reaction was stirred at room temperature for 30 min, when saturated NaHCO₃ solution (5 mL) was added to the reaction mixture and the product was extracted with EtOAc (3 \times 30 mL). The combined organic layers were dried (MgSO₄), filtered and concentrated under reduced pressure, and the residue was chromatographed, giving the desired nitroquinoline **25** (23.3 mg, 82%), as a light yellow solid. Mp 146–148 °C. IR (KBr, ν): 3447, 3422, 1636, 1607, 1524, 831, 762 and 692 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.70 (1H, s, H-4), 8.24 (1H, d, J = 8.5, H-5), 7.99 (1H, d, J = 7.9, H-8), 7.91 (1H, td, J = 7.7 and 1.4, H-6), 7.72 (1H, dd, J = 6.9 and 1.0, H-7), 7.68–7.65 (2H, m, H-2' and H-6') and 7.50 (t, 3H, J = 3.3, H-3', H-4' and H-5'). ¹³C NMR (75 MHz, CDCl₃): δ = 152.1 (C-2), 148.4 (C-8a), 144.0 (C-3), 137.1 (C-1'), 132.9 (C-6), 132.7 (C-4), 129.8 (C-5), 129.6 (C-3', C-4' and C-5'), 128.8 (C-8), 128.6 (C-7), 128.5 (C-6'), 128.1 (C-2') and 125.6 (C-4a). HRMS (ESI⁺) calcd. for C₁₅H₁₁N₂O₂ ([M + 1]⁺) m/z = 251.0815; found: m/z = 251.0819.

2-Phenyl-3-aminoquinoline (26)

A mixture of PPh₃ (47.0 mg, 0.18 mmol) and 3-nitroquinoline **25** (18.9 mg, 0.07 mmol) in PhMe (1 mL) was treated with MoO₂-Cl₂(DMF)₂ (2.8 mg, 0.008 mmol). The reaction mixture is heated under reflux for 72 h. Then, the solvent was removed under reduced pressure and the crude material was purified by chromatography to give 2-phenyl-3-aminoquinoline **26** (8.5 mg, 52%) as a yellow solid, mp 121–123 °C (Lit.: 123 °C).³³ IR (KBr, ν): 3321, 2924, 1614, 1435, 1354, 1190, 881, 766 and 700 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.03–8.00 (1H, m, H-8), 7.75 (2H, dt, J = 6.6 and 1.7, H-2' and H-6'), 7.64–7.60 (1H, m, H-4), 7.56–7.51 (2H, m, H-6 and H-7), 7.49–7.40 (3H, m, H-3', H-4' and H-5'), 7.34 (1H, s, H-4) and 3.98 (2H, bs, NH₂). ¹³C NMR (75 MHz, CDCl₃): δ = 150.7 (C-2), 142.8 (C-3), 138.4 (C-8a), 138.1 (C-1'), 129.3 (C-8), 129.1 (C-4a), 129.0 (C-2' y C-6') 128.9 (C-6), 128.7 (C-7), 126.7 (C-4'), 125.7 (C-5), 125.4 (C-3') and 116.1 (C-4).

Quindoline (1)

A solution of 2-phenyl-3-nitroquinoline **25** (15.61 mg, 0.06 mmol) in CH₂Cl₂ (0.5 mL) was treated with DPPE (27.1 mg, 0.07 mmol); the solvent was evaporated under a N₂ atmosphere and the remaining solid mixture was heated at 150 °C for 5 h. Then,



the crude material was purified by chromatography, affording quindoline (**1**, 11 mg, 82%), as a yellow solid, mp 201–203 °C.^{34,5d} The ¹H and ¹³C NMR spectroscopic data of this synthetic compound were in agreement with those of synthetic and natural quindoline.

Phosphazene 27

In order to ensure an intimate mixture of reagents, PPh₃ (70 mg, 0.27 mmol) was added to a solution of 2-phenyl-3-nitroquinoline (**25**, 19.4 mg, 0.08 mmol) in CH₂Cl₂ (0.5 mL). The solvent was evaporated under high vacuum in a N₂ atmosphere, and the resulting solventless solid mixture was heated at 150 °C for 4 h. The crude material was purified by chromatography to give phosphazene **27** (33.4 mg, 87%) as a yellow solid, mp 117–119 °C. IR (KBr, ν): 3053, 2959, 2849, 2779, 1416, 1360, 1271, 1107, 747 and 694 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ = 8.05 (2H, dd, H-2' and H-6'), 7.97 (1H, d, J = 8, H-8), 7.74–7.66 (6H, m, 3 \times H-2'' and 3 \times H-6''), 7.57–7.48 (3H, m, 3 \times H-4'), 7.47–7.38 (9H, m, 3 \times H-3'', 3 \times H-5'', H-3', H-4' and H-5'), 7.32 (1H, dd, J = 7.5 and 8, H-7), 7.24 (2H, m, H-5 and H-6), and 6.97 (1H, bs, H-4). ¹³C NMR (75 MHz, CDCl₃): δ = 121.4 (d, ³ J_{P-C} = 10.4, C-4), 124.5 (C-7), 125.0 (C-5), 125.5 (C-6), 127.3 (H-3' and H-5'), 127.5 (H-4'), 128.7 (d, ³ J_{P-C} = 12.0, 3 \times C-3'' and 3 \times C-5''), 129.0 (2C, C-4a and C-8), 129.4 (C-8a), 130.3 (C-2' and C-6'), 130.5 (d, ¹ J_{P-C} = 100.3, 3 \times C-1''), 131.9 (d, ⁴ J_{P-C} = 2.6, 3 \times H-4''), 132.6 (d, ² J_{P-C} = 9.8, 3 \times C-2'' and 3 \times C-6''), 141.6 (d, ² J_{P-C} = 33.8, C-3), 143.7 (C-1') and 159.0 (d, ³ J_{P-C} = 22.8, C-2). ³¹P NMR (188.31 MHz, CDCl₃): δ = 3.97. HRMS (ESI⁺) calcd. for C₃₃H₂₆N₂P ([M + 1]⁺) m/z = 481.1828; found: m/z = 481.1830.

Computational methods

Conformational searches for the reactants, transition structures (TS) and products were run using the conformational search module of Hyperchem with the MM+ method.³⁵ Selected structures were then successively optimized at the B3LYP/6-31G* and M062X/6-311+G** level single point was performed.³⁶ This level has been shown as a suitable level of theory for this type of structures.²⁷

Frequency calculations were made to confirm the nature of the stationary points and to evaluate their thermochemical properties. The molecular orbitals of the reactants were calculated to analyze the frontier orbital interactions at the M062X/6-311+G** level of theory. Intrinsic reaction coordinate (IRCs) calculations were run to verify the connectivity between reactants, TSs and products. To examine the most important interactions in the TSs, natural bond orbital calculations were performed and Wiberg bond indexes (WBIs) analyzed.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors gratefully acknowledge Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, PUE IQUIR

2016) and Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, PICT 2018-1933 and PICT 2019-3969) for financial support. E. N. T. also thanks ANPCyT for her doctoral fellowship. SOS acknowledges to AvH Foundation for support.

Notes and references

- G. V. Subbaraju, J. Kavitha, D. Rajasekhar and J. I. Jimenez, *J. Nat. Prod.*, 2004, **67**, 461–462.
- D. S. Jang, E. J. Park, Y.-H. Kang, B.-N. Su, M. E. Hawthorne, J. Schunke Vigo, J. G. Graham, F. Cabieses, H. H. S. Fong, R. G. Mehta, J. M. Pezzuto and A. D. Kinghorn, *Arch. Pharmacol. Res.*, 2003, **26**, 585–590.
- O. Souza Chaves, Y. C. Ferreira Teles, M. Morais de Oliveira Monteiro, L. G. Mendes Junior, M. F. Agra, V. de Andrade Braga, T. M. Sarmiento Silva and M. F. Vanderlei de Souza, *Molecules*, 2017, **22**, 94.
- J. F. Liu, Z. Y. Jiang, R. R. Wang, Y. T. Zheng, J. J. Chen, X. M. Zhang and Y. B. Ma, *Org. Lett.*, 2007, **9**, 4127–4129.
- (a) P. T. Parvatkar, P. S. Parameswaran and S. G. Tilve, *Curr. Org. Chem.*, 2011, **15**, 1036–1057; (b) J. Lavrado, R. Moreira and A. Paul, *Curr. Med. Chem.*, 2010, **17**, 2348–2370; (c) L. R. Whittell, K. T. Batty, R. P. M. Wong, E. M. Bolitho, S. A. Fox, T. M. E. Davis and P. E. Murray, *Bioorg. Med. Chem.*, 2011, **19**, 7519–7525; (d) J. Lavrado, G. G. Cabal, M. Prudêncio, M. M. Mota, J. Gut, P. J. Rosenthal, C. Díaz, R. C. Guedes, D. J. V. A. dos Santos, E. Bichenkova, K. T. Douglas, R. Moreira and A. Paulo, *J. Med. Chem.*, 2011, **54**, 734–750.
- D. Dwuma-Badu, J. S. K. Ayim, N. Y. Y. Fiagbe, J. E. Knapp, P. L. Schiff Jr and D. J. Slatkin, *J. Pharm. Sci.*, 1978, **67**, 433–434.
- (a) L. Yang, C. He, Sudunabuqi, X. Bao, X. Wang and W. Ao, *Biochem. Syst. Ecol.*, 2020, **93**, 104163; (b) S. W. Yang, M. Abdel-Kader, S. Malone, M. C. M. Werkhoven, J. H. Wisse, I. Bursuker, K. Neddermann, C. Fairchild, C. Raventos-Suarez, A. T. Menendez, K. Lane and D. G. I. Kingston, *J. Nat. Prod.*, 1999, **62**, 976–983; (c) Z. Y. Xu, Y. F. Xi, W. Y. Zhou, L. L. Lou, X. B. Wang, X. X. Huang and S. J. Song, *Biochem. Syst. Ecol.*, 2020, **92**, 104089.
- (a) S. D. Ablordeppey, C. D. Hufford, R. F. Borne and D. Dwuma-Badu, *Planta Med.*, 1990, **56**, 416–417; (b) A. N. Tackie, M. H. M. Sharaf, P. L. Schiff Jr, G. L. Boye, R. C. Crouch and G. E. Martin, *J. Heterocycl. Chem.*, 1991, **28**, 1429–1435.
- (a) A. Paulo, E. T. Gomes and P. J. Houghton, *J. Nat. Prod.*, 1995, **58**, 1485–1491; (b) K. Cimanga, T. De Bruyne, L. Pieters, M. Claeys and A. Vlietnick, *Tetrahedron Lett.*, 1996, **37**, 1703–1706; (c) D. M. Fort, J. Litvak, J. L. Chen, Q. Lu, P. W. Phuan, R. Cooper and D. E. Bierer, *J. Nat. Prod.*, 1998, **61**, 1528–1530.
- (a) C. E. Hadden, M. H. M. Sharaf, J. E. Guido, R. H. Robins, A. N. Tackie, C. H. Phoebe Jr, P. L. Schiff Jr and G. E. Martin, *J. Nat. Prod.*, 1999, **62**, 238–240; (b) R. C. Crouch, A. O. Davis, T. D. Spitzer, G. E. Martin, M. H. M. Sharaf, P. L. Schiff Jr, C. H. Phoebe and A. N. Tackie, *J. Heterocycl. Chem.*, 1995,



- 32, 1077–1080; (c) J.-L. Pousset, M.-T. Martin, A. Jossang and B. Bodo, *Phytochemistry*, 1995, **39**, 735–736.
- 11 M. H. M. Sharaf, P. L. Schiff Jr, A. N. Tackie, C. H. Phoebe Jr and G. E. Martin, *J. Heterocycl. Chem.*, 1996, **33**, 239–243.
- 12 (a) K. Blinov, M. Elyashberg, E. R. Martirosian, S. G. Molodtsov, A. J. Williams, A. N. Tackie, M. H. M. Sharaf, P. L. Schiff Jr, R. C. Crouch, G. E. Martin, C. E. Hadden, J. E. Guido and K. A. Mills, *Magn. Reson. Chem.*, 2003, **41**, 577–584; (b) M. H. M. Sharaf, P. L. Schiff Jr, A. N. Tackie, C. H. Phoebe Jr, L. Howard, C. Myers, C. E. Hadden, S. K. Wrenn, A. O. Davis, C. W. Andrews, D. Minick, R. L. Johnson, J. P. Shockcor, R. C. Crouch and G. E. Martin, *Magn. Reson. Chem.*, 1995, **33**, 767–778; (c) A. N. Tackie, G. L. Boye, M. H. M. Sharaf, P. L. Schiff Jr, R. C. Crouch, T. D. Spitzer, R. L. Johnson, J. Dunn, D. Minick and G. E. Martin, *J. Nat. Prod.*, 1993, **56**, 653–670; (d) M. H. M. Sharaf, P. L. Schiff Jr, A. N. Tackie, C. H. Phoebe Jr, R. L. Johnson, D. Minick, C. W. Andrews, R. C. Crouch and G. E. Martin, *J. Heterocycl. Chem.*, 1996, **33**, 789–797.
- 13 (a) E. L. Larghi, A. B. J. Bracca, A. A. Arroyo Aguilar, D. A. Heredia, J. L. Pergomet, S. O. Simonetti and T. S. Kaufman, *Curr. Top. Med. Chem.*, 2015, **17**, 1683–1707; (b) A. B. J. Bracca, D. A. Heredia, E. L. Larghi and T. S. Kaufman, *Eur. J. Org. Chem.*, 2014, 7979–8003; (c) M. V. Méndez, A. B. J. Bracca and T. S. Kaufman, *Synthesis*, 2018, **50**, 1417–1429.
- 14 M. V. Méndez, S. O. Simonetti, T. S. Kaufman and A. B. J. Bracca, *New J. Chem.*, 2019, **43**, 10803–10813.
- 15 M. V. Méndez, D. A. Heredia, E. L. Larghi, A. B. J. Bracca and T. S. Kaufman, *RSC Adv.*, 2017, **7**, 28298–28307.
- 16 T. D. Spitzer, R. C. Crouch, G. E. Martin, M. H. M. Sharaf, P. L. Schiff Jr, A. N. Tackie and L. B. Gilbert, *J. Heterocycl. Chem.*, 1991, **28**, 2065–2070.
- 17 A. I. Calderon, A. Hodel, J.-L. Wolfender, M. P. Gupta, M. Correa and K. Hostettmann, *Nat. Prod. Res.*, 2013, **27**, 1335–1342.
- 18 (a) H. C. Pal and S. K. Katiyar, *Molecules*, 2016, **21**, 1758; (b) O. A. Olajide, H. S. Bhatia, A. C. de Oliveira, C. W. Wright and B. L. Fiebich, *Eur. J. Med. Chem.*, 2013, **63**, 333–339; (c) C. Ansah and K. B. Mensah, *Ghana Med. J.*, 2013, **47**, 137–147; (d) H. C. Pal, R. Prasad and S. K. Katiyar, *Sci. Rep.*, 2017, **7**, 1498.
- 19 (a) C.-F. Chang, C.-Y. Huang, Y.-C. Huang, K.-Y. Lin, Y.-J. Lee and C.-J. Wang, *Synth. Commun.*, 2010, **40**, 3452–3466; (b) T. Naveen, S. Maity, U. Sharma and D. Maiti, *J. Org. Chem.*, 2013, **78**, 5949–5954.
- 20 R. Ballini, G. Bosica, D. Fiorini and A. Palmieri, *Green Chem.*, 2005, **7**, 825–827.
- 21 (a) A. Awasthi, P. Yadav, S. Yadav and D. K. Tiwari, *Adv. Synth. Catal.*, 2022, **364**, 41–46; (b) V. Y. Shuvalov, A. S. Rupp, A. S. Fisyuk, A. K. Kuratova, A. A. Nefedov and G. P. Sagitullina, *ChemistrySelect*, 2019, **4**, 1696–1699.
- 22 (a) P. Molina, M. Alajarin, A. Vidal and M. C. Foces-Foces, *Tetrahedron*, 1995, **51**, 12127–12142; (b) Y. Matsuno, M. Mitsunaga, J. Oda, M. Furuki, S. Shoji, T. Kitamura and Y. Shibata, *US Pat.*, US9650350, 2017; (d) P. Molina, M. Alajarin, P. Sanchez-Andrada, J. Elguero and M. L. Jimeno, *J. Org. Chem.*, 1994, **59**, 7306–7315.
- 23 (a) M. Pattarawarapan, D. Yamano, N. Wiriya, S. Yimklan and W. Phakhodee, *J. Org. Chem.*, 2020, **85**, 13330–13338; (b) M. Alajarin, A. Vidal and M.-M. Ortin, *Tetrahedron Lett.*, 2003, **44**, 3027–3030; (c) T. Alaime, M. Daniel, M.-A. Hiebel, E. Pasquinet, F. Suzenet and G. Guillaumet, *Chem. Commun.*, 2018, **54**, 8411–8414; (d) R. S. Foster, J. P. A. Harrity and H. Jakobi, *Org. Lett.*, 2012, **14**, 4858–4861; (e) P. Molina, M. Alajarin, P. Sánchez-Andrada, J. S. Carrió, M. Martínez-Ripoll, J. E. Anderson, M. L. Jimeno and J. Elguero, *J. Org. Chem.*, 1996, **61**, 4289–4299.
- 24 (a) S. Ramírez-Rave, M. T. Ramírez-Apan, H. Tlahuext, D. Morales-Morales, R. A. Toscano and J.-M. Grevy, *J. Organomet. Chem.*, 2016, **814**, 16–24; (b) F. Schömborg, I. Vilotijevic, K. Wagner and Y. Zi, *Org. Lett.*, 2020, **22**, 3407–3411.
- 25 (a) H. Majgier-Baranowska, J. D. Williams, B. Li and N. P. Peet, *Tetrahedron Lett.*, 2012, **53**, 4785–4788; (b) G. W. Gribble, *J. Chem. Soc., Perkin Trans. 1*, 2000, 1045–1075.
- 26 (a) R. J. Sundberg, *J. Org. Chem.*, 1965, **30**, 3604–3610; (b) J. I. G. Cadogan and M. J. Todd, *J. Chem. Soc. C*, 1969, 2808–2813; (c) K. Zhang, A. El Bouakher, H. Lévaïque, J. Bignon, P. Retailleau, M. Alami and A. Hamzé, *J. Org. Chem.*, 2019, **84**, 13807–13823; (d) M. Castiñeira Reis, M. Marín-Luna, C. Silva López and O. N. Faza, *ACS Omega*, 2018, **3**, 7019–7026.
- 27 T. V. Nykaza, A. Ramirez, T. S. Harrison, M. R. Luzung and A. T. Radosevich, *J. Am. Chem. Soc.*, 2018, **140**, 3103–3113.
- 28 A. Pokluda, M. Kohout, J. Chudoba, M. Krupička and R. Cibulka, *ACS Omega*, 2019, **4**, 5012–5018.
- 29 The calculation of the Yamaguchi's spin contamination at the um062x/6-31g* level affords a contribution of the triplet state to the free energy value of less than 2%; hence it was not considered for the calculations.
- 30 H. Wagner, S. Bladt and V. Rickl, *Drug Analysis: A Thin Layer Chromatography Atlas*, Springer, Heidelberg, Germany, 2nd edn, 2009, p. 360.
- 31 L. Zheng, Z. Zeng, Q. Yan, F. Jia, L. Jia and Y. Chen, *Adv. Synth. Catal.*, 2018, **360**, 4037–4042.
- 32 (a) R. Sanz, J. Escribano, M. R. Pedrosa, R. Aguado and F. J. Arnáiz, *Adv. Synth. Catal.*, 2007, **349**, 713–718; (b) A. W. Freeman, U. Urvoy and M. E. Criswel, *J. Org. Chem.*, 2005, **70**, 5014–5019.
- 33 J. Letessier and H. Detert, *Synthesis*, 2012, 290–296.
- 34 H. Peng, X. Chen, Y. Chen, Q. He, Y. Xie and C. Yang, *Tetrahedron*, 2011, **67**, 5725–5731.
- 35 *Hyperchem Professional Release 7.52*, Hypercube, Inc., 2005.
- 36 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr,



J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev,

A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, *Gaussian 09, Revision D.01*, Gaussian, Inc., Wallingford CT, 2013.

